SAR442085 is a monoclonal antibody that targets the CD38 protein on certain cells.
On February 4, 2022, it was announced that Sanofi will no longer continue development on SAR442085 in multiple myeloma.
| SparkCures ID | 355 |
|---|---|
| Developed By | Sanofi |
| Generic Name | SAR442085 |
| Treatment Classifications | |
| Treatment Targets |
February 04, 2022